The Netherlands
LAVA Therapeutics N.V. is at the forefront of developing groundbreaking cancer treatments through its next-generation bispecific gamma-delta T cell engaging (bsTCE) antibodies. Founded in 2016 and headquartered in The Netherlands, the company specializes in the biotechnology and life sciences industries, with a specific emphasis on medical devices.
The company leverages its expertise in gamma-delta T-cell engagers to create therapeutics that target the Vγ9Vδ2 T-cell subset, known for activating both innate and adaptive immune system cells. Their gamma-delta bsTCEs have shown superior efficacy and safety in preclinical studies, with a focus on minimizing toxicity to healthy tissue while targeting tumor cells. Notably, LAVA Therapeutics N.V. is currently the sole developer of these bispecific antibodies for cancer treatment.
With a robust pipeline, their lead program, LAVA-051, focuses on the CD1d antigen, relevant for conditions like multiple myeloma and various leukemias. This program is set to advance to a Phase I/IIa study in Q1 2021. The company's last significant financial backing was a $83 million Series C investment on September 17, 2020, funded by investors including Gilde Healthcare, Versant Ventures, Redmile Group, MRL Ventures Fund, Sanofi Ventures, Ysios Capital, Novo Ventures, and Pureos Bioventures.
